Fundamental Analysis of ZOMEDICA CORP(NYSEARCA:ZOM) stock

Fundamental Rating

We assign a fundamental rating of 4 out of 10 to ZOM. ZOM was compared to 195 industry peers in the Health Care Equipment & Supplies industry. ZOM has a great financial health rating, but its profitability evaluates not so good. ZOM is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ZOM has reported negative net income.

ZOM had a negative operating cash flow in the past year.

In the past 5 years ZOM always reported negative net income.

ZOM had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of ZOM (-13.64%) is comparable to the rest of the industry.

The Return On Equity of ZOM (-14.39%) is better than 62.56% of its industry peers.

		Industry Rank	Sector Rank
ROA	-13.64%
ROE	-14.39%
ROIC	N/A

ROA(3y)-8.76%

ROA(5y)-104.96%

ROE(3y)-9.18%

ROE(5y)-199.7%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 68.76%, ZOM is doing good in the industry, outperforming 78.46% of the companies in the same industry.

The Profit Margin and Operating Margin are not available for ZOM so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	68.76%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ZOM does not have a ROIC to compare to the WACC, probably because it is not profitable.

ZOM has about the same amout of shares outstanding than it did 1 year ago.

Compared to 5 years ago, ZOM has more shares outstanding

ZOM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

ZOM has an Altman-Z score of 4.98. This indicates that ZOM is financially healthy and has little risk of bankruptcy at the moment.

ZOM's Altman-Z score of 4.98 is fine compared to the rest of the industry. ZOM outperforms 79.49% of its industry peers.

ZOM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	4.98

ROIC/WACCN/A

WACC10.04%

2.3 Liquidity

ZOM has a Current Ratio of 11.06. This indicates that ZOM is financially healthy and has no problem in meeting its short term obligations.

ZOM has a Current ratio of 11.06. This is amongst the best in the industry. ZOM outperforms 93.85% of its industry peers.

A Quick Ratio of 10.49 indicates that ZOM has no problem at all paying its short term obligations.

The Quick ratio of ZOM (10.49) is better than 92.82% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	11.06
Quick Ratio	10.49

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ZOM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -102.88%.

The Revenue has grown by 33.05% in the past year. This is a very strong growth!

EPS 1Y (TTM)-102.88%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-66.67%

Revenue 1Y (TTM)33.05%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2Q19.17%

3.2 Future

ZOM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.99% yearly.

ZOM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 25.89% yearly.

EPS Next Y56.09%

EPS Next 2Y41.42%

EPS Next 3Y25.99%

EPS Next 5YN/A

Revenue Next Year37.23%

Revenue Next 2Y25.58%

Revenue Next 3Y25.89%

Revenue Next 5YN/A

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZOM. In the last year negative earnings were reported.

Also next year ZOM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ZOM's earnings are expected to grow with 25.99% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y41.42%

EPS Next 3Y25.99%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ZOM does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ZOMEDICA CORP

NYSEARCA:ZOM (4/26/2024, 3:32:23 PM)

After market: 0.133 0 (0%)

0.133

+0 (+2.23%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap130.33M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-13.64%
ROE	-14.39%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	68.76%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.1

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	11.06
Quick Ratio	10.49
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-102.88%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y56.09%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)33.05%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ZOMEDICA CORP (ZOM)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens